Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia

Konstantinidis, Lazaros; Mantel, Irmela; Zografos, Léonidas; Ambresin, Aude

doi:10.1007/s00417-009-1117-3

Cited by 16 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A single injection of intravitreal bevacizumab (1.25 mg) seems to be effective to improve VA and to decrease mean central foveal thickness. Several case reports of treatment with one or more intravitreal injections of bevacizumab (1.25 mg) [81,82,84] or ranibizumab (0.5 mg) [85,86] injections with a mean 6-month follow-up corroborated the improvement in VA, the resolution of subretinal and intraretinal fluid on OCT and the regression of SRNV with cessation of SRNV leakage in all cases. On the other hand, in a more recent retrospective series of 5 eyes with proliferative idiopathic juxtafoveolar retinal telangiectasis II treated with intravitreal bevacizumab with a longer follow-up (2 years), best-corrected VA was unchanged or improved after treatment [69].…”

Section: Retinal Telangiectasiasmentioning

confidence: 73%

See 1 more Smart Citation

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

et al. 2012

View full text Add to dashboard Cite

Primitive retinal vascular abnormalities are benign conditions of the retinal circulation that comprise vascular tumors and telangiectasias. The principal vascular tumors of the retina include retinal capillary hemangioma, cavernous hemangioma of the retina, racemose hemangiomatosis of the retina and retinal vasoproliferative tumor, while primary retinal telangiectasias include Coats’ disease, Leber’s miliary aneurysms and idiopathic juxtafoveal telangiectasias. In most cases, these alterations result in significant visual impairment due to exudation determined by the structural abnormalities of the retinal vasculature. The aim of this review is to assess the different clinical and diagnostic features of the single pathological entities and to discuss the available treatment modalities including the onset of intravitreal antivascular endothelial growth factor therapy.

show abstract

Section: Retinal Telangiectasiasmentioning

confidence: 73%

“…Several case series in the literature investigated the effects of bevacizumab or ranibizumab but with limited (12 months or less) follow-up [80,81,82,83,84,85,86,87]. A single injection of intravitreal bevacizumab (1.25 mg) seems to be effective to improve VA and to decrease mean central foveal thickness.…”

Section: Retinal Telangiectasiasmentioning

confidence: 99%

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

et al. 2012

View full text Add to dashboard Cite

show abstract

“…10 Verificámos que os agentes antiangiogénicos permitiram uma melhoria significativa e sustentada na MAVC e na EF, até aos 60 meses de tratamento. Os nossos resultados estão de acordo com outros descritos para o ranibizumab [37][38][39][40][41] e para o bevacizumab em estudos com menor tempo de seguimento. 36,42 A variação da MAVC relativamente ao valor inicial foi progressivamente menor para os diferentes tempos de seguimento, embora sempre superiores à MAVC inicial (p < 0,05), o que poderá ser explicado pela idade mais avançada, com componente associado de DMI e consequentemente MAVC mais baixas, bem como pela progressão da atrofia associada à miopia e à própria NVC.…”

Section: Discussionunclassified

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

et al. 2014

View full text Add to dashboard Cite

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes. Material and Methods:In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment. Results:The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9µm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001). Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

show abstract

“…The concept of a similar pathogenesis of neovascular AMD and MacTel type 2 was the rationale to study VEGF-inhibitors as a treatment option for neovascular MacTel type 2 ( Fig. 10; Charbel Issa et al, 2007b;Jorge et al, 2006;Karagiannis et al, 2009;Konstantinidis et al, 2009;Mandal et al, 2007;Mondal et al, 2010;Roller et al, 2011;Ruys et al, 2007;Shanmugam et al, 2007). Jorge and co-workers were the first to show a positive effect of bevacizumab in a patient with a juxtafoveolar neovascular membrane .…”

Section: Proliferative Stagementioning

confidence: 99%

Macular Telangiectasia Type 2

Heeren

Holz

Issa

2013

Microperimetry and Multimodal Retinal Imaging

View full text Add to dashboard Cite

Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules, retinal pigment plaques, foveal atrophy, and neovascular complexes. Fluorescein angiography shows telangiectatic capillaries predominantly temporal to the foveola in the early phase and a diffuse hyperfluorescence in the late phase. High-resolution optical coherence tomography (OCT) may reveal disruption of the photoreceptor inner segment-outer segment border, hyporeflective cavities at the level of the inner or outer retina, and atrophy of the retina in later stages. Macular telangiectasia type 2 shows a unique depletion of the macular pigment in the central retina and recent therapeutic trials showed that such depleted areas cannot re-accumulate lutein and zeaxanthin after oral supplementation. There have been various therapeutic approaches with limited or no efficacy. Recent clinical trials with compounds that block vascular endothelial growth factor (VEGF) have established the role of VEGF in the pathophysiology of the disease, but have not shown significant efficacy, at least for the nonneovascular disease stages. Recent progress in structure-function correlation may help to develop surrogate outcome measures for future clinical trials.In this review article, we summarize the current knowledge on macular telangiectasia type 2, including the epidemiology, the genetics, the clinical findings, the staging and the differential diagnosis of the disease. Findings using retinal imaging are discussed, including fluorescein angiography, OCT, adaptive optics imaging, confocal scanning laser ophthalmoscopy, and fundus autofluorescence, as are the findings using visual function testing including visual acuity and fundus-controlled microperimetry. We provide an overview of the therapeutic approaches for both non-neovascular and neovascular disease stages and provide a perspective of future directions including animal models and potential therapeutic approaches.

show abstract

Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia

Cited by 16 publications

References 8 publications

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

Macular Telangiectasia Type 2

Contact Info

Product

Resources

About